

The stimulation of macrophage prostaglandin E₂ and thromboxane B₂ secretion by *Streptococcus mutans* insoluble glucans

Yoshimitsu Abiko, Yasuko Shibata, Kazuo Fukushima⁺, Seidai Murai*
and Hisashi Takiguchi

Departments of Biochemistry and ⁺ Microbiology, Nihon University School of Dentistry at Matsudo, 2-870-1, Sakaecho-Nishi, Matsudo, Chiba 271 and *Department of Conservative Dentistry, Nihon University School of Dentistry, 1-8-13, Kanda-Surugadai, Chiyoda-Ku, Tokyo 101, Japan

Received 21 December 1982; revision received 22 February 1983

The effect of insoluble glucan synthesized by *Streptococcus mutans* on [³H]arachidonate metabolites secretion from peritoneal macrophages was studied. Insoluble glucans stimulated [³H]arachidonate release and secretion of prostaglandin E₂ and thromboxane B₂ from macrophages. In contrast, commercial soluble glucan (dextran) did not induce [³H]arachidonate release.

Macrophage	Prostaglandin E ₂	Thromboxane B ₂	<i>Streptococcus mutans</i>
	Insoluble glucans	Periodontal disease	

1. INTRODUCTION

Dental plaque microorganisms and their metabolic products such as toxins, enzymes and polysaccharides have been shown to induce gingivitis and periodontitis [1]. Bacterial polysaccharides are known to be present in significant quantities in dental plaque [2]. A prime determinant of the ability of *S. mutans* to form dental plaque is the capacity of the organism to synthesize high *M_r* glucans from sucrose, including highly branched polymer glucans that have α -1,6 and α -1,3-glucosidic linkages [3]. Ivanyi has reported that branched dextran from dental plaque is, additionally, a B-cell mitogen for human lymphocytes and that the incidence and magnitude of the response to branched dextran increased in patients with gingival periodontal disease when compared to subjects with clinically healthy gingiva [4]. Arachidonic acid metabolites appear to be involv-

ed in the regulation of inflammation [5]. PGE₂ has been detected in human gingival tissue with periodontal diseases [6], and PG-like products have been detected in the culture media of gingival culture [7]. Administration of PGE₂ in organ culture [8] or in vivo [9] induces bone resorption. The presence in periodontal disease gingiva of increased levels of TXB₂ may reflect the accumulation of inflammatory cells within the gingiva [10]. TXB₂ is the stable end product of TXA₂, which has been shown to possess potent vascular smooth muscle contraction activity [11] and to induce irreversible platelet aggregation [12]. It is known that macrophages have a key role in mediating inflammatory reactions [13] and macrophages are a presumable source of PGE₂ and TXB₂ release [14].

Here we present evidence that insoluble glucans obtained from *S. mutans* induce PGE₂ and TXB₂ secretion from macrophages in cell culture.

2. MATERIALS AND METHODS

2.1. Macrophage culture

Peritoneal exudate cells were induced by the in-

Abbreviations: *S. mutans*, *Streptococcus mutans*, PGE₂, prostaglandin E₂, TXB₂, thromboxane B₂, AA, arachidonic acid

jection of sterile 0.1% glycogen (0.30 μ m filter) into female guinea pigs. After 3 days, animals were anesthetized with ether, rapidly bled from the heart and perfused with saline solution. Then, peritoneal exudate cells were harvested with RPMI 1640 medium containing 5 mM Tris-HCl (pH 7.4), 100 units/ml penicillin G, 100 μ g/ml streptomycin sulfate and 0.38% sodium citrate. When red blood cells were present, these were lysed with hypotonic saline (0.2%) for 30 s and diluted with an equal volume of 1.6% NaCl solution. The cells were washed twice with RPMI 1640 medium without sodium citrate and plated at 1×10^6 cells/well (Linbro tissue culture multi-well plate, 2.0 cm²). After incubation for 2 h at 37°C in 5% CO₂ in air, the non-adherent cells were washed off twice.

2.2. *S. mutans* glucans

Insoluble glucans from various species of *S. mutans* were prepared as in [15]. Estimation of α -1,3 glucosidic linkage contents in glucans was carried out by measuring the hydrolysis with excess dextranase. The reaction mixture contained 100 mM sodium acetate buffer (pH 6.0), 2 units dextranase (from *Penicillium* sp., Sigma Chemical Co.) and 1 mg glucan. Hydrolysis of glucan was carried out at 37°C for 24 h. The hydrolyzed sugars were determined by phenol-sulfuric acid reaction. The suspended insoluble glucans were sterilized in the autoclave. Aggregated insoluble glucans were resuspended by sonication and diluted with RPMI medium for use.

2.3. Assay for [³H]arachidonate release

Fresh RPMI 1640 medium (0.5 ml) containing 0.1% bovine serum albumin (BSA) and 0.15 μ Ci [5,6,8,9,11,12,14,15-³H] arachidonic acid; 127 Ci/mmol (Amersham) was added to adherent macrophage cells in the tissue culture multi-well plate. After 16 h incubation, the radiolabeled macrophages were washed twice with Hank's balanced salt solution; and fresh medium containing 0.1% BSA with or without glucans was added. The radioactivity released into the medium was determined after incubation for varying times.

2.4. Chromatography of [³H]PGE₂ and [³H]TXB₂

Radioactive products in the medium were extracted and determined as in [16]. As standards, 360 nmol PGE₂ and TXB₂ were also mixed with

Table 1.

Effect of various insoluble glucans on arachidonate release

Inducer added	[³ H]arachidonate released (dpm)	Relative activity
Controls		
None	9562 \pm 315	1.00
Dextran	9258 \pm 941	0.97
Insoluble glucans from <i>S. mutans</i> strain (serotype)		
6715 (g)	25986 \pm 1876 ^a	2.72
OMZ-176 (d)	13746 \pm 2330 ^b	1.44
PS-14 (f)	11425 \pm 982 ^b	1.20
QP-50 (c)	10652 \pm 660 ^b	1.11

^a $P \leq 0.001$, ^b $P \leq 0.05$ compared with zero.

Macrophage culture (1.0×10^6 cells/well) were prelabeled with [³H]arachidonic acid for 16 h. The cells were incubated with or without each inducer for 4 h at 37°C in 5% CO₂ in air. The concentrations of insoluble glucans and dextran were 500 μ g/ml. All results are expressed as the mean \pm SD ($n = 4$)




Fig. 1. Time-dependent release of [³H]arachidonate. Macrophage cultures (1×10^6 cells/well) were prelabeled with [³H]arachidonic acid for 16 h. The cells were incubated with insoluble glucan obtained from *S. mutans* 6715 (—▲— 250 μ g/ml) or without (—●—).

Results show the mean \pm SEM of 4 different exp.

Table 2

[³H]arachidonate metabolites elicited by insoluble glucan

Incubation time	Insoluble glucan added (6715)	PGE ₂		TXB ₂	
		³ H-released (dpm)	Rel. act. (%)	³ H-released (dpm)	Relative activity (%)
4 h	None	33 ± 15	100.0	67 ± 8	100.0
	500 µg/ml	359 ± 52	1087.8 ^a	938 ± 200	1400.0 ^a
8 h	None	116 ± 16	100.0	136 ± 18	100.0
	500 µg/ml	1257 ± 199	1083.6 ^a	1506 ± 303	1107.4 ^a

^a*P* ≤ 0.01 compared with none

[³H]Arachidonate metabolites released from macrophages after addition of 0.5 ml RPMI 1640 medium containing 500 µg/ml insoluble glucan suspension were extracted and chromatographed on silical-gel G plates, using the solvent system described in the text. Spots of chromatographed authentic samples were detected by iodine vapor and radioactivity in the areas was counted. The values are expressed as mean ± SD (*n* = 4).

the extracts. The plates (silica gel-G) were developed with a solvent system [benzene:1,4-dioxane:acetic acid (60:30:1)] chosen to separate PGE₂ and TXB₂ and then visualized by exposure to iodine vapor. The areas corresponding to authentic PGE₂ and TXB₂ on the chromatograms were cut out and the radioactivity was determined using a liquid scintillation counter.

3. RESULTS

We have found that the percentage solubilization of glucans differed between various *S. mutans*; 6715 (11%), QP-50 (36%), OMZ-176 (58%) and PS-14 (68%); suggesting that glucan from *S. mutans* 6715 has the highest amount of α-1,3 glucosidic linkage content. The effect of insoluble glucans synthesized by several strains of *S. mutans* on [³H]AA release from macrophages was examined. About 55% of [³H]AA radioactivity added was incorporated into macrophages and 70% of the incorporated radioactivity was distributed into the phospholipid fraction under our incubation conditions (not shown). Insoluble glucan from *S. mutans* strain 6715 caused the highest [³H]AA release, whereas commercial soluble dextran (*M_r* 5–40 × 10⁶) did not induce [³H]AA release. The [³H]AA release stimulated by various concentrations of insoluble glucan from *S. mutans* 6715 occurred in a time-dependent manner over 8 h (Fig. 1). The [³H]AA metabolites released in culture medium by stimulation with 500 µg/ml

insoluble glucan from *S. mutans* 6715 were identified by thin-layer chromatography. At 500 µg/ml, insoluble glucan from *S. mutans* 6715 caused an 11-fold increase in secretion of [³H]PGE₂ and a 14-fold increase in [³H]TXB₂ secretion at 4 h and an 11-fold increase in secretion of both [³H]PGE₂ and [³H]TXB₂ at 8 h as shown in table 2.

4. DISCUSSION

This study demonstrates that insoluble glucan from *S. mutans* can dramatically induce glycogen-elicited guinea pig peritoneal macrophages to secrete PGE₂ and TXB₂. The magnitude of response is dependent on the duration of incubation time.

Considerable evidence has accumulated regarding the chemical structure of insoluble glucans from various strains of *S. mutans*. The large proportion of α-1,3-glucosidic linkages found in insoluble glucan explains the insoluble nature of this polymer and the consecutive α-1,3-glucosidic linkages from long chains as the backbone of a highly branched insoluble glucan [3]. Since morphology and size of insoluble glucan from *S. mutans* has the fibrillar form (28 × 5.2 nm) [17], and sonicated insoluble glucan has a high *M_r* (> 1.5 × 10⁷) [18], macrophage phagocytosis of insoluble glucan might be related to their [³H]AA metabolism.

Several serotypes of *S. mutans* may be responsible for dental plaque formation, but it is not clear

whether one serotype is more virulent than another. We have found that glucan from *S. mutans* 6715 had the highest α -1,3 glucosidic linkage content. When compared with our data in table 1, insoluble glucans from *S. mutans* 6715 caused the highest [^3H]AA release, it suggests that [^3H]AA release from macrophages may depend on the proportion of α -1,3 glucosidic linkage contents of glucan. We have not investigated here the functional mechanisms of α 1,3 glucosidic linkage glucan on the stimulation of AA release. In [19], alveolar macrophage phagocytosis of zymosan increased the release of AA and PGs; in contrast, phagocytosis of inert latex particles had no effect [19]. The insoluble polysaccharide β -1,3 glucan is the active component of zymosan for producing hyperplasia and hyperfunction of the reticulo-endothelial system [20]. The following possibilities may therefore be considered: membrane changes occurring after interiorization of the cell surface by phagocytosis of α -1,3 glucosidic linkage glucan may play roles of Ca^{2+} efflux, activation of membrane phospholipase A_2 or C, or release of lysosomal phospholipase A_2 related to AA release.

TXB_2 and PGE_2 may contribute to inflammatory processes by causing chemotaxis of leukocytes, vascular permeability and histamine release [21,22]. Prior treatment of rat gingival epithelial surface with *Streptococcus* hyaluronidase allowed penetration of the polysaccharide resulting in destructive changes in rat gingiva [23].

Thus, our data suggest that insoluble glucan from *S. mutans* in dental plaque may contribute to pathophysiological inflammation and bone resorption in periodontal tissues through the induction of TXB_2 and PGE_2 release from macrophages. Experiments to clarify the detailed mechanism of α -1,3 glucosidic linkage insoluble glucan on AA release from macrophages are in progress.

ACKNOWLEDGEMENTS

This study was supported in part by a Nihon University Scientific Research grant for 1982 and a grant-in-aid for Encouragement of Young Scientists from the Ministry of Education, Science and Culture of Japan, 1982.

REFERENCES

- [1] Bahn, A.N. (1970) *J. Periodontol.* 41, 603-610.
- [2] Wood, J.M. (1969) *Arch. Oral Biol.* 14, 161-168.
- [3] Hamada, S. and Slade, H.D. (1980) *Microbiol. Rev.* 44, 331-384.
- [4] Ivanyi, L. (1977) *Clin. Immun. Immunopathol.* 7, 123-129.
- [5] Higgs, G.A. and Salmon, J.A. (1979) *Prostaglandins* 17, 737-746.
- [6] Goodson, J.M., Dewhirst, F.E. and Brunetti, A. (1974) *Prostaglandins* 6, 81-85.
- [7] Gomes, B.C., Hausmann, E., Weinfeld, N. and DeLuca, C. (1976) *Calcif. Tiss. Res.* 19, 285-293.
- [8] Klein, D.C. and Raisz, L.G. (1970) *Endocrinology* 86, 1436-1440.
- [9] Goodson, J.M., McClatchy, K. and Revell, C. (1974) *J. Dent. Res.* 53, 670-677.
- [10] Rifkin, B.R. and Tai, H.H. (1981) *J. Periodont. Res.* 16, 194-198.
- [11] Ellis, E.F., Oelz, O., Roberts, L.J. ii, Payne, N.A., Sweetman, B.J., Nies, A.S. and Oates, J.A. (1976) *Science* 193, 1135-1137.
- [12] Hamberg, M., Svensson, J. and Samuelsson, B. (1975) *Proc. Natl. Acad. Sci. USA* 72, 2994-2998.
- [13] Davis, P. and Allison, A.C. (1976) in: *Immunology of the macrophage*, pp. 427-461, Academic Press, New York.
- [14] Brune, K., Glatt, M., Kalin, H. and Peskar, B.A. (1978) *Nature* 274, 261-263.
- [15] Fukushima, K., Motoda, R. and Ikeda, T. (1981) *J. Dent. Res.* 60, 1707-1712.
- [16] Stenson, W.F., Nickells, M.W. and Atkinson, J.P. (1981) *Prostaglandins* 21, 675-689.
- [17] Newbrun, E., Lacy, R. and Christie, T.M. (1971) *Arch. Oral Biol.* 16, 863-872.
- [18] Inoue, M. and Koga, T. (1979) *Infect. Immun.* 25, 922-931.
- [19] Hsueh, W., Kuhn, C. iii and Needleman, P. (1979) *Biochem. J.* 184, 345-354.
- [20] Riggi, S.J. and Di Luzio, N.R. (1961) *Amer. J. Physiol.* 200, 297-300.
- [21] Boot, J.R., Dawson, W. and Kitchen, E.A. (1976) *J. Physiol.* 257, 47p-48p.
- [22] Velo, G.P., Fracasso, M.E., Leone, R. and Milanino, R. (1981) in: *The Prostaglandin System*, pp. 97-108, Plenum, New York.
- [23] Gaffar, A., Coleman, E.J. and Marcussen, H.W. (1981) *J. Periodontol.* 52, 197-205.